Semaglutide: The GLP-1 Receptor Agonist
A single-target incretin agonist
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a single-target incretin compound, and the baseline of the modern metabolic research class. Tirzepatide adds the GIP receptor to it; retatrutide adds both GIP and glucagon.
The pathway
- GLP-1 receptor: an incretin target linked in research to glucose-dependent insulin signaling, gastric emptying, and satiety pathways. Semaglutide acts on this single receptor with high potency and a long half-life.
Where it sits in the family
Semaglutide (single) to tirzepatide (dual, +GIP) to retatrutide (triple, +glucagon). As the single-target anchor of the class, it is the most-studied member and the comparator the newer multi-agonists are measured against.
What the research has examined
Semaglutide has one of the largest clinical evidence bases in the class. A 68-week phase 3 obesity trial (Wilding et al., *NEJM* 2021, STEP 1) studied its effect on body weight, and a large cardiovascular-outcomes trial (Lincoff et al., *NEJM* 2023, SELECT) examined cardiovascular endpoints in people with overweight or obesity without diabetes. These are findings from controlled research trials.
Limitations and open questions
- Investigational supply. Research compound, not an approved product; not for human use.
- Class-typical adverse events. Gastrointestinal effects were the most frequently reported in trials.
- Single-target ceiling. As a GLP-1-only agonist it doesn't engage the GIP or glucagon pathways, the rationale behind the dual and triple agonists now under study.
For laboratory research use only. Not for human consumption.